Aktuellt
SENASTE
Redeye provides a short research update following the positive phase Ib results with lead candidate ALZ-101 published by Alzinova last week. Overall, we are encouraged to learn that the candidate met the primary endpoint of safety and tolerability, while demonstrating a clear immunological response related to treatment. We raise our base case valuation to SEK12 (10) as we see an increased likelihood of approval (LoA) for ALZ-101 following the results.
LÄS MER
